TuHURA Biosciences (NASDAQ:HURA) Cut to “Sell” at Wall Street Zen

Wall Street Zen cut shares of TuHURA Biosciences (NASDAQ:HURA) from a hold rating to a sell rating in a research note published on Sunday.

Several other equities analysts also recently issued reports on HURA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TuHURA Biosciences in a research note on Thursday, January 22nd. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.00.

TuHURA Biosciences Price Performance

NASDAQ:HURA opened at $1.97 on Friday. TuHURA Biosciences has a one year low of $0.41 and a one year high of $4.44. The company has a market cap of $119.62 million, a PE ratio of -3.94 and a beta of -0.30. The firm’s 50 day simple moving average is $1.23 and its 200 day simple moving average is $1.66.

Institutional Investors Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in HURA. Bank of America Corp DE bought a new stake in TuHURA Biosciences in the fourth quarter worth approximately $59,000. Jane Street Group LLC acquired a new stake in shares of TuHURA Biosciences during the 1st quarter worth approximately $69,000. Geode Capital Management LLC grew its position in shares of TuHURA Biosciences by 111.4% during the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock worth $1,300,000 after buying an additional 307,260 shares during the period. Intech Investment Management LLC bought a new stake in shares of TuHURA Biosciences in the 2nd quarter valued at $29,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of TuHURA Biosciences during the 2nd quarter valued at $27,000. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.